Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ginkgo Bioworks reports strong Q4 earnings, eyes biopharma growth

Ginkgo Bioworks reports strong financial performance and strategic growth in Q4 2022, focusing on downstream value share and biosecurity leadership.
While facing challenges with negative EBITDA, the company aims to drive efficiency, expand biosecurity initiatives, and capitalize on opportunities in biopharma and API manufacturing.
With a solid financial foundation, Ginkgo is well-positioned to leverage its expertise in programming cells and proprietary protein sequences for future growth and market expansion.

Ginkgo Bioworks reports strong Q1 growth and eyes global expansion

Ginkgo Bioworks showcased strong performance in Cell Engineering and Biosecurity revenue, emphasizing platform improvement and strategic partnerships.
While facing challenges in enterprise sales and operating expenses, the company is well-positioned for growth through international biosecurity expansion and biopharma focus.
Opportunities lie in global biosecurity initiatives, biopharma sales pipeline, and persistent monitoring programs, signaling a promising future for Ginkgo.

Ginkgo Bioworks posts robust Q2 results, eyes revenue diversification

Ginkgo Bioworks reported strong growth in revenue and active programs, with a focus on operational efficiencies and customer relationships.
Transitioning to success-based pricing models and task-specific data training positions the company for revenue diversification and enhanced customer value.
While facing market challenges and funding constraints, Ginkgo is strategically expanding its offerings and driving towards profitability through operational enhancements.

Ginkgo Bioworks reports strong Q3 performance and biosecurity opportunities

Ginkgo Bioworks reports strong performance with revenue growth and increased active programs.
The company's strengths lie in AI progress, diverse customer base, and biosecurity applications.
Challenges include deal timing, competitive positioning, and managing operational expenses.
Opportunities include tech licensing deals, AI-driven efficiency, and synergies between biosecurity and cell engineering.

Ginkgo Bioworks navigates revenue challenges with strategic growth initiatives

Ginkgo Bioworks faces revenue challenges from program dynamics but is strategically positioned for growth through R&D investments and partnerships.
The company's focus on innovation, efficiency, and biosecurity infrastructure underscores its commitment to leading in biotech R&D.
Opportunities in expanding partnerships, enhancing automation technology, and standardizing interfaces signal a promising path for Ginkgo's future growth.
Despite short-term revenue setbacks, Ginkgo's strategic initiatives and industry positioning bode well for long-term success and market leadership.

Ginkgo Bioworks targets EBITDA breakeven by 2026 amid revenue challenges

Ginkgo Bioworks is navigating challenges in revenue growth while focusing on cost reductions and operational efficiency to achieve EBITDA breakeven by 2026.
The company's strategic shift towards biopharma and bioAg sectors showcases flexibility and growth potential in serving large companies with research budgets.
Introduction of 'Lab Data as a Service' and focus on streamlining workflows present opportunities for scalability and revenue enhancement.
Despite challenges in revenue outlook and restructuring efforts, Ginkgo remains committed to operational success and financial sustainability.

Ginkgo Bioworks advances cost-saving goals amidst revenue challenges

Ginkgo Bioworks progresses towards financial targets amidst revenue challenges and aggressive cost-saving measures.
Strategic focus on automation, biosecurity, and revenue diversification positions the company for future growth.
Challenges include revenue decline, employee impact from layoffs, and balancing cost reduction with innovation.
Opportunities lie in new revenue streams, margin accretive initiatives, and market differentiation through mission-driven approach.

Ginkgo Bioworks reports mixed Q3 results, focuses on growth strategies

Ginkgo Bioworks showed strength in cost-cutting, revenue generation, and strategic focus, despite a negative adjusted EBITDA.
Challenges include financial pressures, margin concerns, and potential risks in resource utilization and funding stability.
Opportunities lie in new offerings, AI capabilities, market expansion, and revenue scale for improved profitability.
Management's emphasis on cost reduction, revenue growth, and innovation positions the company for long-term success and sustainability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intellia Therapeutics

The average analyst following Ginkgo Bioworks thinks the stock can climb 140% from recent prices over the next 12 months or so. The consensus price target on Intellia Therapeutics suggests it can more than triple your money from recent prices.

2 Growth Stocks That Could Rocket 144% and 202% Higher This Year, According to Wall Street

Bristol-Myers

Pfizer

Healthcare stocks trudged through what was a terrible 2023 for the sector. While the S&P 500 rose by 24% during 2023, the healthcare sector managed paltry returns of 0.3%.

3 Healthcare Stocks at 52-Week Lows: Buy or Bye?

Recursion Pharmaceuticals

Cathie Wood bought shares of Meta Platforms, Recursion Pharmaceuticals, and Ginkgo Bioworks this week. Shares of Meta have more than tripled since bottoming out in late 2022.

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought This Week

Illumina

The companies plan to join forces to set up pathogen monitoring programs utilizing Illumina technology across Concentric's global network  BOSTON and SAN DIEGO , Jan. 15, 2024 /PRNewswire/ -- Concentric by Ginkgo, the biosecurity and public health unit of Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it has entered into a Co-Marketing Agreement with Illumina, Inc. (Nasdaq: ILMN), a global leader in DNA sequencing and array-based technologies, to partner on expanding biosecurity capabilities globally. Concentric is building a global pathogen monitoring network—a "bioradar" system —in countries around the world to detect, characterize, and rapidly respond to biological threats and help drive informed decision-making in support of global health objectives.

Concentric by Ginkgo and Illumina collaborate to deploy biosurveillance technologies around the world

Costco

Eli Lilly

Eli Lilly's valuation is through the roof, but it's not just hot air. Ginkgo Bioworks could become a great long-term pickup.

3 Pricey Stocks I'll Be Watching Like a Hawk in 2024

Expects to meet 2023 new program and revenue guidance ranges Ended the year with nearly $950 million in cash and cash equivalents, a strong balance sheet providing multi-year runway as Ginkgo sees operational efficiencies in the business Strong growth among blue chip pharma and biotech ("biopharma") customers including Pfizer, Novo Nordisk, Merck and Boehringer Ingelheim Management to highlight updates today at the 42nd Annual J.P. Morgan Healthcare Conference at 9:45 a.m.

Ginkgo Bioworks Provides Business Updates at J.P. Morgan Healthcare Conference

CRISPR Therapeutics

Teladoc

Cathie Wood has loaded up her portfolio with tomorrow's potential healthcare game changers. The superstar investor's commitment to innovation helped her flagship fund jump more than 60% last year.

3 Cathie Wood Stocks to Start Off Your New Year Right

BOSTON , Jan. 8, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the formation of its new Biopharma Advisory Board. This council of experts from across the biopharmaceutical industry will provide critical insight into the development of Ginkgo's core platform service offerings across target discovery, drug discovery, optimization, and manufacturing.

Ginkgo Bioworks Announces Inaugural Members of New Biopharma Advisory Board

Beam Therapeutics

Guardant Health Inc

Guardant Health has tremendous opportunities in early cancer detection and cancer therapy selection. Beam Therapeutics and Intellia Therapeutics are pioneers in gene editing.

4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024

Iovance Biotherapeutics

Wall Street analysts following Ginkgo Bioworks and Iovance Biotherapeutics think these stocks can rocket higher in 2024. A consensus target of $4.75 on Ginkgo Bioworks suggests it can more than triple from recent prices.

2 Growth Stocks That Could Rocket 149% to 210% Higher in 2024, According to Wall Street

Alphabet

Tesla

Some of these stocks already have delivered big gains, but still have plenty of room to run. Others, thanks to their game-changing technologies, could see their share prices take off at any moment.

5 Innovative Stocks That Could Score a Win for Your Portfolio in 2024

Archer Aviation

Cerus

Invitae

Verve Therapeutics

Cathie Wood's ARK Innovation ETF isn't afraid to go against Wall Street and the S&P 500. But in some cases, the consensus agrees with the famed ETF manager.

Analysts Agree These 8 Cathie Wood Stock Picks Will Soar In 2024

Collaboration enhanced the productivity of Biogen's AAV production platform to help accelerate efforts to bring novel gene therapies to patients worldwide BOSTON , Jan. 4, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the successful completion of the gene therapy collaboration they announced with Biogen in May 2021. Together, the companies aimed to redefine the industry standard for manufacturing recombinant adeno-associated virus (AAV)-based vectors.

Ginkgo Bioworks Completes Program with Biogen to Boost Productivity of Gene Therapy Manufacturing Platform

BOSTON , Jan. 3, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Co-Founder and CEO, Jason Kelly, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:45 a.m.

Ginkgo Bioworks Announces Participation in the 42nd Annual J.P. Morgan Healthcare Conference

The integration of synthetic biology and artificial intelligence could be a powerful mixture. Ginkgo Bioworks, a pioneer in synthetic biology, has partnered with Google Cloud to explore the possibilities.

This Artificial Intelligence Stock Could Be Like Buying Amazon in 1997

Ginkgo Bioworks is a cell programming specialist that has partnered with many big companies. It is in a very early stage, but has a lot of promising opportunities in the long run.

Could Ginkgo Bioworks Stock Help You Become a Millionaire?

OneOne is a French biotech startup developing a comprehensive suite of agricultural microbial solutions Ginkgo will support OneOne in its agricultural biologicals and synthetic biology R&D Ginkgo will initially conduct in vitro and in planta assays to test OneOne's concept. In a planned second phase, Ginkgo's Strain Optimization Services and ultra high throughput encapsulated screening will provide OneOne with optimized strains for nitrogen fixation OneOne expects to use those strains to move to field trials and minimize its time-to-market PARIS and BOSTON , Dec. 20, 2023 /PRNewswire/ -- OneOne Biosciences, a French startup building a comprehensive suite of agricultural microbial solutions for farmers, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership.

OneOne Biosciences Partners with Ginkgo Bioworks to Advance its Platform and Nitrogen Fixation Microbial Product

The EIC has tapped FGen and partners to work on developing a sustainable, alternative approach to milk production using only CO2 and electricity FGen will focus on ultra-high throughput screening of bacteria engineered to convert CO2 into a major whey protein Utilizing microbial systems — instead of livestock — to produce valuable food ingredients will be critical for sustainable bioproduction of foods, medicines, and chemicals BASEL, Switzerland , Dec. 19, 2023 /PRNewswire/ -- FGen AG, a subsidiary of Ginkgo Bioworks (NYSE: DNA), based in Switzerland, has been awarded funding through the European Innovation Council's (EIC) Pathfinder Challenge program. This is part of an international research consortium that aims to develop a new, sustainable approach to milk protein production using only carbon dioxide and electricity.

FGen AG, a Ginkgo Bioworks Subsidiary, Awarded Funding Through European Innovation Council's Pathfinder Programme For Sustainable Milk Protein Production Project

Algae-based biotechnology can be used to drive forward clean energy solutions, such as sustainable aviation fuel, yet scaling algal biotechnologies for such purposes faces major barriers The DOE has awarded a Ginkgo-led team — which also includes partners from Pacific Northwest National Laboratory, Colorado School of Mines, and Global Algae Innovations — to build revolutionary algal crop protection solutions The team will leverage its expertise in applied algal biology, metagenomics, high-throughput screening, and adaptive laboratory evolution to work to design algal crop protection solutions as more environmentally-friendly alternatives to conventional chemical pesticides, while enhancing productivity BOSTON , Dec. 19, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that a Ginkgo-led team — including partners from the Pacific Northwest National Laboratory, Colorado School of Mines, and Global Algae Innovations — has been awarded funding through the U.S. Department of Energy's (DOE) Bioenergy Technologies Office (BETO). The scope of the project will be to develop a new approach to algal crop protection, inspired by integrated pest management strategies used for terrestrial crops.

U.S. Department of Energy Awards Team Led by Ginkgo Bioworks Funding to Develop Algal Crop Protection Solutions

GreenLab is creating an enzymatic solution — to be grown and scaled within corn plants — to degrade PFAS, often called "forever chemicals," a major health and environmental concern Ginkgo has been tapped to discover and develop an enzyme that will be critical to the success of GreenLab's PFAS degradation application Through a partnership with Allonnia, this project is the first step in a path that could potentially lead to the first-ever commercially deployed enzymatic solution for PFAS degradation JONESBORO, Ark. and BOSTON , Dec. 19, 2023 /PRNewswire/ -- GreenLab, an emerging next generation plant-biotechnology company producing complex proteins in corn, today announced a new partnership with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity.

GreenLab Selects Ginkgo Enzyme Services to Develop Novel Enzyme That Breaks Down 'Forever Chemicals'

Cathie Wood's focus on disruptive technologies could be a winning strategy over the long term. Ginkgo Bioworks and Recursion Pharmaceuticals are two of her more intriguing holdings in the biotech industry.

2 Cathie Wood Stocks That Might Be Smart Buys Right Now

AbCellera Biologics

One of the biggest stories of the year has been the rise of AI in every industry. This trend will hit biotech stocks no less than any others.

AI Meets Biotech: 3 Top Stocks Transforming Medical Science

Chewy

Etsy

These stocks are down but not out -- thanks to their solid long-term prospects. This list includes healthcare innovators and two exciting e-commerce companies.

5 Beaten-Down Stocks That Could Soar in 2024

Ginkgo, under a grant from the Bill & Melinda Gates Foundation, will work to develop a live cell therapeutic that can produce antibodies to fight human immunodeficiency virus (HIV) and/or malaria directly in the body Ginkgo will apply its cell engineering expertise towards creating a fundamentally new cell-based therapeutic delivery modality which could change the future of biologics delivery in medicine BOSTON , Dec. 13, 2023 /PRNewswire/ -- – Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, has received a grant from the Bill & Melinda Gates Foundation to develop a novel cell-based technology for improving protein therapeutics delivery for patients in low- and middle-income countries (LMICs). Protein therapeutics have transformed the standard of care for many diseases — the best known example being insulin for diabetes — and have helped to extend lives across the world, thanks to revolutionizing treatments of diseases such as anemia, cancers, and certain genetic disorders.

Ginkgo Bioworks Receives Grant to Develop Innovative Live Cell Delivery Platform of Antibody Therapeutics for Treating HIV and Malaria

Moderna

Stocks won't automatically become more expensive when we shift into a new year. But those that have struggled this year and have strong long-term outlooks could rebound at any point.

News for Ginkgo Bioworks Holdings Stock (DNA)